Feb 21 (Reuters) - Oncogenex Pharmaceuticals Inc OGXI.O :
* Oncogenex Pharmaceuticals, Inc. announces phase 2 apatorsen data for two clinical trials presented at the American Society Of Clinical Oncology (asco) 2017 genitourinary cancers symposium
* Oncogenex Pharmaceuticals Inc- clinical data from trials in bladder and prostate cancers demonstrated apatorsen was well-tolerated Source text for Eikon: ID:nCNWC83D2a Further company coverage: OGXI.O